DOYLESTOWN, Pa., Feb. 05, 2019 (GLOBE NEWSWIRE) -- Kannalife, Inc. (“Kannalife”) (KLFE), a bio-pharmaceutical and phyto-medical company, is pleased to announce and congratulate the Company’s spokesperson – former NFL and Kansas City Chiefs Hall of Famer – Nick Lowery for winning the 2018 CNBC Stock Draft with his picks of Amazon (AMZN), Goldman Sachs (GS) and AMD (AMD).
Nick’s incredible acumen for business played itself out in 2018 as he was awarded top honors in the annual CNBC Stock Draft. We also extend our appreciation and recognition for his accomplishments and humanitarian efforts. Nick was just honored with the 2019 Steinberg DeNicola Humanitarian Award during Superbowl LIII week in Atlanta, and will be the honoree at the American Cancer Society’s 58th Annual Evening of Hope on February 16th, 2019 in Phoenix, Arizona.
Dean Petkanas, CEO of Kannalife, stated, “It is an honor and a privilege to have Nick Lowery as a part of our team at Kannalife in support of our efforts to combat neurodegenerative and oxidative stress related diseases in the emerging field of cannabinoid therapeutics.”
About Kannalife, Inc. – A Phyto-Medical Company™
Kannalife, Inc. is a phyto-medical company involved in the research and development of novel therapeutic agents designed to be neuroprotectants and immuno-modulators. Kannalife is currently conducting research and development at the Pennsylvania Biotechnology Center in Doylestown, PA, for target drug candidates to treat hepatic encephalopathy (“HE”), chronic traumatic encephalopathy (“CTE”) and Chemotherapy Induced Peripheral Neuropathy (“CIPN”). HE and CTE are oxidative stress-related diseases that affect cognitive and behavioral functions. CIPN is a neurodegenerative condition that afflicts patients undergoing chemotherapy with symptoms that include numbness, tingling, and pain.
For more information, visit www.kannalife.com.
FORWARD-LOOKING DISCLAIMER AND DISCLOSURES
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks and uncertainties. The statements in this press release have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act.
Public Relations Contact:
Chief Executive Officer